Madrigal Pharmaceuticals, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for MDGL, updated each market day.
MDGL AI Sentiment
AI sees no strong directional signal for Madrigal Pharmaceuticals, Inc. Common Stock stock over the next 10 market days.
Prediction date: Sept. 22, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Madrigal Pharmaceuticals, Inc. Common Stock
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Sector
Exchange
Market Cap
$12,346,844,934
Cap Tier
Employees
915
Headquarters
WEST CONSHOHOCKEN, PA
Listed Since
Feb. 6, 2007
Website
MDGL Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MDGL Volatility
Madrigal Pharmaceuticals, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
